Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Susan Branford, Timothy P. Hughes et al.|Leukemia|2012Cited by 417
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Eva Hoster et al.|The Lancet|2016Cited by 401
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaRüdiger Hehlmann, Susanne Saußele, Michael Lauseker et al.|Journal of Clinical Oncology|2011Cited by 323
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan‐Niklas Eckardt, Jan Moritz Middeke, Friedrich Stölzel et al.|Journal of Hematology & Oncology|2022Cited by 58